Ewen Lescop

Dr. Ewen Lescop

French National Centre for Scientific Research, Paris, Île-de-France, France
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2007 in Journal of Magnetic Resonance
Verified
Journal Article
Closed access
ELEwen Lescop
Ewen Lescop
PSPaul Schanda
Paul Schanda
BBBernhard Brutscher
Bernhard Brutscher

28 December 2015 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
MPMarie-Aude Plamont
Marie-Aude Plamont
EBEmmanuelle Billon-Denis
Emmanuelle Billon-Denis
SMSylvie Maurin
Sylvie Maurin
CGCarole Gauron
Carole Gauron
FPFrederico M. Pimenta
Frederico M. Pimenta
AGArnaud Gautier
Arnaud Gautier
Significance: We developed a small protein tag enabling fluorescent labeling of proteins in living cells and in multicellular organisms through the specific binding and activation of a cell-permeant and nontoxic fluorogenic ligand. This tag, called Yellow Fluorescence-Activating and absorption-Shifting Tag (Y-FAST), was engineered by directed evolution from the Photoactive Yellow Protein. Y-FAST distinguishes itself from other labeling methods because the fluorogen binding is highly dynamic and fully reversible. Apart from providing new opportunities in superresolution imaging and biosensor design, this feature enables rapid switching on and off of the fluorescence of a fusion protein by addition or withdrawing of the fluorogenic ligand, opening exciting ways to perform sequential multiplexing imaging.

29 May 2008 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
MJMalene Ringkjobing Jensen
Malene Ringkjobing Jensen
KHKlaartje Houben
Klaartje Houben
ELEwen Lescop
Ewen Lescop
LBLaurence Blanchard
Laurence Blanchard
RRRob W. H. Ruigrok
Rob W. H. Ruigrok
MBMartin Blackledge
Martin Blackledge

1 October 2014 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
IFIoana FERECATU
Ioana FERECATU
SGSergio Gonçalves
Sergio Gonçalves
MGMarie-Pierre Golinelli
Marie-Pierre Golinelli
MCMartin Clémancey
Martin Clémancey
AMAlain Martelli
Alain Martelli
CBCécile Bouton
Cécile Bouton
The Hsp70 family protein mortalin is an essential chaperone that is frequently enriched in cancer cells and exists in various subcellular sites, including the mitochondrion, plasma membrane, endoplasmic reticulum, and cytosol. Although the molecular mechanisms underlying its multiple subcellular localizations are not yet clear, their functional significance has been revealed by several studies. In this study, we examined the nuclear fractions of human cells and found that the malignantly transformed cells have more mortalin than the normal cells. We then generated a mortalin mutant that lacked a mitochondrial targeting signal peptide. It was largely localized in the nucleus, and, hence, is called nuclear mortalin (mot-N). Functional characterization of mot-N revealed that it efficiently protects cancer cells against endogenous and exogenous oxidative stress. Furthermore, compared with the full-length mortalin overexpressing cancer cells, mot-N derivatives showed increased malignant properties, including higher proliferation rate, colony forming efficacy, motility, and tumor forming capacity both in in vitro and in vivo assays. We demonstrate that mot-N promotes carcinogenesis and cancer cell metastasis by inactivation of tumor suppressor protein p53 functions and by interaction and functional activation of telomerase and heterogeneous ribonucleoprotein K (hnRNP-K) proteins.

3 September 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
CAChristelle Arrondel
Christelle Arrondel
SMSophia Missoury
Sophia Missoury
RSRozemarijn Snoek
Rozemarijn Snoek
JPJulie Patat
Julie Patat
GMGiulia Menara
Giulia Menara
GMGéraldine Mollet
Géraldine Mollet
N6-threonyl-carbamoylation of adenosine 37 of ANN-type tRNAs (t6A) is a universal modification essential for translational accuracy and efficiency. The t6A pathway uses two sequentially acting enzymes, YRDC and OSGEP, the latter being a subunit of the multiprotein KEOPS complex. We recently identified mutations in genes encoding four out of the five KEOPS subunits in children with Galloway-Mowat syndrome (GAMOS), a clinically heterogeneous autosomal recessive disease characterized by early-onset steroid-resistant nephrotic syndrome and microcephaly. Here we show that mutations in YRDC cause an extremely severe form of GAMOS whereas mutations in GON7, encoding the fifth KEOPS subunit, lead to a milder form of the disease. The crystal structure of the GON7/LAGE3/OSGEP subcomplex shows that the intrinsically disordered GON7 protein becomes partially structured upon binding to LAGE3. The structure and cellular characterization of GON7 suggest its involvement in the cellular stability and quaternary arrangement of the KEOPS complex.

1 March 2010 in Journal of Magnetic Resonance
Verified
Journal Article
Closed access
ELEwen Lescop
Ewen Lescop
TKThomas Kern
Thomas Kern
BBBernhard Brutscher
Bernhard Brutscher